EBM Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, T.
Right arrow Articles by Bing, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, T.
Right arrow Articles by Bing, R. J.
Proceedings of the Society for Experimental Biology and Medicine 225:200-206 (2000)
© 2000 Society for Experimental Biology and Medicine


Review Article

Nitric Oxide Donors

Tadahiko Yamamoto and Richard J. Bing1,


Department of Experimental Cardiology, Huntington Medical Research Institutes, Pasadena, California 91101

Nitric oxide (NO) donors are pharmacologically active substances that release NO in vivo or in vitro. NO has a variety of functions such as the release of prostanoids, inhibition of platelet aggregation, effect on angiogenesis, and production of oxygen free radicals. This report discusses the chemical and pharmacological characteristics of NO donors, their effect on platelet function and cyclooxygenase, their cardiac action including myocardial infarction, and release of superoxide anions. This review stresses NO tolerance and the effect of NO donors on angiogenesis in myocardial infarction and in solid tumors.




This article has been cited by other articles:


Home page
CirculationHome page
R. Cavolli, K. Kaya, A. Aslan, O. Emiroglu, S. Erturk, O. Korkmaz, M. Oguz, R. Tasoz, and U. Ozyurda
Does Sodium Nitroprusside Decrease the Incidence of Atrial Fibrillation After Myocardial Revascularization?: A Pilot Study
Circulation, July 29, 2008; 118(5): 476 - 481.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
N. Mastrodimou, F. Kiagiadaki, and K. Thermos
The Role of Nitric Oxide and cGMP in Somatostatin's Protection against Retinal Ischemia
Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 342 - 349.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. Carrier, I. Brochu, A. J. de Brum-Fernandes, and P. D'Orleans-Juste
The Inducible Nitric-Oxide Synthase Modulates Endothelin-1-Dependent Release of Prostacyclin and Inhibition of Platelet Aggregation ex Vivo in the Mouse
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 972 - 978.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
C. Cabou, P. D. Cani, G. Campistron, C. Knauf, C. Mathieu, C. Sartori, J. Amar, U. Scherrer, and R. Burcelin
Central Insulin Regulates Heart Rate and Arterial Blood Flow: An Endothelial Nitric Oxide Synthase Dependent Mechanism Altered During Diabetes
Diabetes, December 1, 2007; 56(12): 2872 - 2877.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
M. L. Salmi, K. E. Morris, S. J. Roux, and D. M. Porterfield
Nitric Oxide and cGMP Signaling in Calcium-Dependent Development of Cell Polarity in Ceratopteris richardii
Plant Physiology, May 1, 2007; 144(1): 94 - 104.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Zhang and S. A. Fisher
Conditioning Effect of Blood Flow on Resistance Artery Smooth Muscle Myosin Phosphatase
Circ. Res., March 16, 2007; 100(5): 730 - 737.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
C. Sciorati, B. G. Galvez, S. Brunelli, E. Tagliafico, S. Ferrari, G. Cossu, and E. Clementi
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy
J. Cell Sci., December 15, 2006; 119(24): 5114 - 5123.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. G. Herman and S. Moncada
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X. Sun, K. M. Kaltenbronn, T. H. Steinberg, and K. J. Blumer
RGS2 Is a Mediator of Nitric Oxide Action on Blood Pressure and Vasoconstrictor Signaling
Mol. Pharmacol., March 1, 2005; 67(3): 631 - 639.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Schubert, U. Krien, I. Wulfsen, D. Schiemann, G. Lehmann, N. Ulfig, R. W. Veh, J. R. Schwarz, and H. Gago
Nitric Oxide Donor Sodium Nitroprusside Dilates Rat Small Arteries by Activation of Inward Rectifier Potassium Channels
Hypertension, April 1, 2004; 43(4): 891 - 896.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Bertuglia, A. Giusti, and P. Del Soldato
Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheek pouch microcirculation
Am J Physiol Gastrointest Liver Physiol, March 1, 2004; 286(3): G437 - G443.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
M. Klink, M. Cedzynski, A. St Swierzko, H. Tchorzewski, and Z. Sulowska
Involvement of nitric oxide donor compounds in the bactericidal activity of human neutrophils in vitro
J. Med. Microbiol., April 1, 2003; 52(4): 303 - 308.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
S. R. Smukler, L. Tang, M. B. Wheeler, and A. M. F. Salapatek
Exogenous Nitric Oxide and Endogenous Glucose-Stimulated {beta}-Cell Nitric Oxide Augment Insulin Release
Diabetes, December 1, 2002; 51(12): 3450 - 3460.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R D Rakhit and M S Marber
Nitric oxide: an emerging role in cardioprotection?
Heart, October 1, 2001; 86(4): 368 - 372.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society for Experimental Biology and Medicine.